2/2 Multi-Center CLEAN AIR 2 Randomized Control Trial in COPD
Overview
Organization: National Heart, Lung, and Blood Institute
Start Date: 09/2023
End Date: Ongoing
Primary Goal: Goal 4: Increase and sustain research to better understand the prevention, pathogenesis, diagnosis, treatment, and management of COPD.
Secondary Goal(s):
Objective(s):
- Help expand, coordinate, and optimize COPD research efforts
Collaboration: Johns Hopkins University
Activity Type: Research
Activity Description
COPD is a leading cause of death and morbidity worldwide and is attributable to the aggregate burden of toxic gases and particles that individuals inhale during their lifetime. Particulate matter (PM) and nitrogen dioxide (NO2) are common pollutants in indoor environments where adults with COPD spend >90% of their time. We propose a Phase III multi-center randomized sham-controlled trial to test the effectiveness of an air cleaner intervention targeting indoor pollutants (PM and NO2) on quality of life and exacerbation risk reduction among former smokers with COPD (n~770) across multiple clinical practice locations.Audience
General Audience: Researchers
Focused Audience: n/a
Program Reach: National
Type of Area: N/A
Setting: Workplace
Cost and Funding Sources
It was funded through the National Heart, Lung, and Blood Institute and funds to be allotted to grantees.Impact Analysis
Results of their programs are in progress.Advice or Lessons Learned
In process.Contact Information
National Heart, Lung, and Blood Institute
Program Analyst
Bethesda
Maryland